ULBP2 and liver cancer: A mechanistic study involving reprogrammed CSCs from liver cancer revealed that CD44 mRNA functions as a competing endogenous RNA (ceRNA) that specifically binds microRNA (miR)-34a, thereby preventing the activating NKG2DL, UL16 binding protein 2 (ULBP2), from degradation.